Sequenom develops and manufactures tests for the molecular diagnostics market. Its lab-developed tests are primarily focused on prenatal and ophthalmological diseases and conditions. Tests include MaterniT21 Plus (screen for fetal chromosomal abnormalities), HerediT CF (screen for cystic fibrosis genetic mutations), and SensiGene RHD (screen for fetal Rhesus D factor), as well as RetnaGene AMD (predictive test for age-related macular degeneration). The firm formerly offered technology and tools (principally based on its MassARRAY sequencing system) used by researchers, but sold that business in 2014. Sequenom generates about a quarter of sales outside the US. LabCorp acquired Sequenom for $371 million in mid-2016.